Amlodipine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Amlodipine: From Hypertension to Brain Stem Infarction
One-Sentence Summary
Amlodipine is a dihydropyridine L-type calcium channel blocker (CCB) established in clinical practice for hypertension and stable angina pectoris. The TxGNN model predicts it may be effective for Brain Stem Infarction, with 0 clinical trials and 0 publications currently supporting this specific indication. This prediction currently rests on model inference alone, placing it at the lowest evidence tier (L5).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available from ARTG data — Amlodipine is an established antihypertensive and anti-anginal agent |
| Predicted New Indication | Brain Stem Infarction |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 |
| Australia Market Status | Not listed in ARTG (data as at 5 April 2026) |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data was not available in this evidence pack. Based on established pharmacology, Amlodipine blocks L-type voltage-gated calcium channels (VGCCs) in vascular smooth muscle and cardiac cells, producing sustained arterial vasodilation, reduced systemic vascular resistance, and durable blood pressure lowering. Its long half-life (~35–50 hours) produces consistent 24-hour BP control without the reflex tachycardia associated with shorter-acting CCBs.
The proposed mechanistic link to brain stem infarction rests on two theoretical pathways. First, through sustained blood pressure reduction, Amlodipine may reduce the haemodynamic risk factors that predispose to brain stem ischaemia — a stroke subtype driven predominantly by small vessel disease and vertebrobasilar atherosclerosis, both of which are strongly hypertension-dependent. Second, by blocking neuronal L-type VGCCs, Amlodipine may theoretically attenuate post-ischaemic calcium overload, a key mechanism of ischaemic neuronal death, potentially offering a degree of neuroprotection beyond simple BP lowering.
However, these links remain indirect and speculative in the specific context of brain stem infarction. Brain stem infarcts represent a distinct anatomical and haemodynamic subtype for which no published clinical trials or observational studies directly examine Amlodipine as an intervention. The TxGNN prediction is most likely driven by the drug’s well-established proximity in the knowledge graph to cerebrovascular disease nodes (particularly ischaemic stroke and hypertensive end-organ damage), rather than any targeted mechanistic or clinical evidence for this specific indication.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
No ARTG entries were returned for Amlodipine in this data query (as at 5 April 2026). Given that Amlodipine is one of the most widely prescribed antihypertensives globally, clinicians should verify the current ARTG registration status directly via the TGA ARTG public database, as this result likely reflects a data pipeline gap rather than the actual regulatory status of the drug in Australia.
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: There is currently no clinical trial or published literature evidence directly supporting Amlodipine for brain stem infarction. The TxGNN prediction is based on model inference alone (L5), with mechanistic links that are plausible in principle but entirely indirect — no study has examined this specific indication.
To proceed, the following is needed:
- MOA confirmation: Retrieve full mechanism of action data from DrugBank (DB00381) to support or refine the mechanistic rationale
- Targeted literature review: Conduct a structured search for CCB use specifically in brain stem ischaemia, vertebrobasilar stroke, and posterior circulation infarcts — distinct from general ischaemic stroke data
- Regulatory data verification: Confirm current ARTG registration status directly via the TGA ARTG database, and retrieve TGA-approved Product Information for safety review
- Preclinical evidence scoping: Assess whether animal model data for CCBs in posterior fossa or brain stem ischaemia exists to support translation potential
- Safety flag review: Evaluate haemodynamic safety concerns specific to the acute stroke context — in particular, the risk of excessive BP lowering impairing autoregulation in brain stem ischaemia before any clinical trial design proceeds
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.